PureTech to Host Virtual R&D Day for Investors on December 11, 2020
30 Novembre 2020 - 1:00PM
Business Wire
Agenda includes expert-led discussions on
therapeutic opportunities in the lymphatic system, fibrosis and
immuno-oncology
PureTech management to share research and
clinical strategies for leveraging leadership in the lymphatic
system and related immunology with the potential to deliver highly
differentiated medicines
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the
“Company”), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, will host its first R&D Day
on Friday, December 11, 2020, beginning at 9:00 a.m., Eastern Time.
The virtual program will showcase PureTech’s scientific leadership
in lymphatics and related immune pathways and share insights across
its Wholly Owned Pipeline, which includes LYT-100, a clinical-stage
anti-fibrotic and anti-inflammatory product candidate being
advanced for the potential treatment of interstitial lung diseases
and lymphedema, and LYT-200, a product candidate targeting
foundational immunomodulatory mechanisms for the potential
treatment of solid tumors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201130005328/en/
PureTech will host a virtual R&D Day
on Friday, December 11, 2020, beginning at 9:00 a.m., EST. The
program will showcase PureTech’s scientific leadership in
lymphatics and related immune pathways and share insights across
its Wholly Owned Pipeline. Experts will lead discussions on
therapeutic opportunities in the lymphatic system, fibrosis and
immuno-oncology and PureTech management will share research and
clinical strategies with the potential to deliver highly
differentiated medicines. (Graphic: Business Wire)
In addition to presentations by PureTech’s senior team, the
R&D Day will feature talks from renowned scientists and
physicians, including:
- Toby Maher, M.D., professor of clinical medicine and director
of interstitial lung disease at Keck School of Medicine of the
University of Southern California
- Siddhartha Mukherjee, M.D., DPhil, clinician and researcher at
Columbia University and Pulitzer Prize-winning author of The
Emperor of all Maladies and The Gene
- Stanley Rockson, M.D., Allan and Tina Neill professor of
lymphatic research and medicine at Stanford University; chief of
consultative cardiology and director of the Stanford Center for
Lymphatic and Venous Disorders
- Zev Wainberg, M.D., co-director of the UCLA GI Oncology Program
and assistant professor of medicine at UCLA
“PureTech’s inaugural R&D Day is an opportunity to bring
together field-leading experts within our expansive global network
to discuss the unique therapeutic opportunities within lymphatics
and related immunology,” said Daphne Zohar, chief executive officer
of PureTech Health. “We have made great progress across our Wholly
Owned Pipeline, which now includes four product candidates and
three discovery platforms, and we look forward to detailing our
differentiated approach towards addressing major diseases.”
The agenda for PureTech’s R&D Day is:
Opening Remarks
- Welcome from Chris Viehbacher, chairman of PureTech Board of
Directors, and Bob Horvitz, Ph.D., chairman of PureTech R&D
Committee
- Perspectives from Daphne Zohar
Lymphatic Science Overview
- The science underlying our Wholly Owned Pipeline, including the
biology of the BIG Axis, lymphatic system and related immunology:
Joe Bolen, Ph.D., chief scientific officer at PureTech
- A clinical perspective on lymphatics and the need for
innovation in lymphatic disorders and beyond: Stanley Rockson, M.D.
(includes Q&A)
Fibrotic and Inflammatory Conditions – Unmet Need and
LYT-100
- Deep dive into LYT-100 and its potential to treat a range of
conditions involving fibrosis, inflammation and impaired lymphatic
flow: Michael Chen, Ph.D., head of innovation at PureTech
- A pulmonology perspective on interstitial lung diseases,
including IPF and Long COVID, and the unmet need: Toby Maher, M.D.,
Ph.D. (includes Q&A)
- Remarks from Eric Elenko, Ph.D., chief innovation officer at
PureTech
Immuno-Oncology – Prioritizing Targets and Future
Directions
- Perspectives on the field of immuno-oncology, where we are
today and the clinical landscape: Siddhartha Mukherjee, M.D.,
DPhil, and Zev Wainberg, M.D.
- Deep dive into LYT-200 and targeting galectin-9 for a range of
cancer indications: Aleksandra Filipovic, M.D., Ph.D., head of
oncology at PureTech
- Fireside chat: What’s next? The future of immuno-oncology with
Drs. Zev Wainberg and Siddhartha Mukherjee (includes Q&A)
Closing Remarks
- PureTech’s vision for future growth and Q&A session with
the PureTech senior management team
A webcast of the event will be available on the Investors
section of PureTech’s website under Events & Presentations.
To register for PureTech’s R&D Day, please sign up here.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech’s Founded Entities,
is comprised of 24 products and product candidates, including two
that have received U.S. Food and Drug Administration (FDA)
clearance and European marketing authorization. All of the
underlying programs and platforms that resulted in this pipeline of
product candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based
on the Company’s unique insights into the biology of the brain,
immune and gut, or BIG, systems and the interface between those
systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to our
product candidates and approach towards addressing major diseases,
future prospects, developments, and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks and uncertainties that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, our
expectations regarding the potential therapeutic benefits of
PureTech’s product candidates and those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201130005328/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com U.S. media Adam Silverstein +1 917
697 9313 adam@tenbridgecommunications.com
PureTech Health (NASDAQ:PRTC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
PureTech Health (NASDAQ:PRTC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024